Key Takeaways
- Tariffs derailed the year, not the thesis: Revenue guidance cut to ₹800–₹850 crores from ₹900–₹1,000 crores as US trade restrictions pushed Pakhajan utilization below 50%, but a 15-year customer-funded supply agreement and 30% volume growth signal underlying demand intact.
- A 15-year, customer-funded contract is the quarter's structural win: A global MNC is funding the capex for a complex lubricant derivative, validating Yasho's technical capability and shifting the growth conversation from tariff cycles to sticky, long-duration chemistry.
- Balance sheet absorbed the tariff shock, not without strain: Inventory ballooned to 210 days as finished goods piled up on export delays, pushing up gross debt and working capital; management has begun corrective purchasing cuts and targets 160–175 days by March.
- Margins held but the tariff math is being eaten: Gross margins stayed healthy at 42%, and the company insists it will not cut price for volume, yet management conceded "somewhere you need to eat something" on the tariff impact.
- What to watch next quarter: Whether US business recovers to its prior 25% revenue share, whether the ₹45 crores of deferred capex gets the green light, and whether inventory reduction stays on track toward the March target.
The Tariff Shock: What Broke and What Is Recovering
- US exposure, quantified: 25% of revenue comes from the USA, and at least 40% of that US book was affected by the tariff action in Q2, causing exports to miss anticipated growth.
- Utilization collapsed at the new plant: Pakhajan, the company's flagship facility, operated below 50% utilization in Q2 because trade restrictions hit its key export market, directly compressing asset turnover and delaying the path to a 3x target.
- Recovery is tentative but visible: Some US business began returning in the last month and the current month; management hopes to regain the prior 25% revenue share from the US within the current quarter and the next.
- Tariff-level uncertainty remains: Management declined to specify the tariff rate at which Yasho stays competitive, noting only that the historical rate was 6.5% and "we hope for that, we don't know where we'll end up."
- Competitive dynamics are shifting: Intense competition from China is a headwind, but local players gain an edge if the tariff regime persists since they are protected by it; new customers won during this period are expected to be sticky even if tariffs come down, creating a double positive.
Parag Jhaveri: "We're working hard to achieve that. Harshil, I can assure that we are working very hard to assure that margins remain intact. But somewhere you need to eat something, okay? You cannot get"
The 15-Year Supply Agreement: A Customer-Funded Anchor
- Structure of the deal: A 15-year long-term supply agreement with a global MNC for lubricant derivatives, with the customer funding the associated capex; the product is an existing one with some chemistry and process tweaks, not a ground-up new molecule.
- Why it matters for the investment case: The contract converts Yasho from a spot-exposed specialty chemical supplier into a long-duration strategic partner, with the customer's capital commitment removing funding risk from the expansion while locking in volume for over a decade.
- The technical moat at work: Management attributes the win to technical capability that gave the customer confidence Yasho can deliver a product that is "very complex and critical for their application," a signal that the R&D investment is translating into commercial stickiness.
- What management will not say: When asked why the MNC chose to fund the capex rather than build itself, management declined to speculate on the customer's reasoning, and margin details on the contract are protected by an NDA.
Parag Jhaveri: "our capability on a technical side, that has given a confidence to our customer that we can deliver the product what they are looking at, which is very complex and critical for their application."
Revenue: Volume Tells a Different Story Than the Top Line
- The 30% volume growth hidden by mix: Revenue grew only 11% YoY but volume surged 30% because the consumer segment, which carries a high selling price per tonne, degrew while the industrial segment, with a low price per tonne, expanded rapidly; management explicitly measures growth by volume, not top line.
- Revised guidance embeds tariff realism: Full-year revenue is now expected at ₹800–₹850 crores, down from the earlier ₹900–₹1,000 crores, with management stating that if tariffs were removed, revenue would be close to ₹900 crores.
- Export ambition intact: Within 6 to 18 months, exports are targeted to reach almost 70% of total revenue, up from the current mix, supported by REACH registrations that have grown from over 40 to nearly 50 products.
- New customer pipeline building: 10–15% of projected revenue is expected from new customers, and the approval cycle creates a natural barrier: big and medium players take 12–36 months for approvals, while emerging-market approvals take 3–6 months but come with lower margins.
- Pricing environment is bifurcated: Pricing is quite good in Europe due to regulatory work; pricing issues are concentrated outside the USA, mainly in Africa, Asia, and Middle East markets affected by tariffs.
Parag Jhaveri: "we always measure our growth with the volume we sell rather than the top line what we achieve."
Balance Sheet and Working Capital: The Tariff Shock Absorber
- Inventory blew out on tariff-driven export delays: Finished goods inventory rose as shipments stalled while incoming raw material continued to arrive, pushing inventory to 210 days and causing a temporary increase in gross debt and working capital.
- Corrective action underway: Management has initiated measures to reduce raw material purchases and targets bringing inventory down to 160–175 days by March.
- Receivables at a record low: Receivables came down to 60 days, the lowest ever, and management considers this level sustainable, providing a partial offset to the inventory strain.
- Debt repayment has begun: Long-term debt repayment started from April 2025, and the company aims to bring the debt-to-EBITDA multiple down in a phased manner, targeting close to 3.5 or between 3 to 3.5 by FY27, with no intention to reduce absolute debt but a commitment that the ratio will improve drastically in the next two years.
Margins: Defending the Floor While Tariffs Take a Bite
- Gross margins held at 42%: Cost control and operational discipline protected gross margins despite Pakhajan's sub-50% utilization, and management expects gross margins to remain in the 38–42% band while working toward 40% plus.
- EBITDA margin commitment: The company wants to adhere to a 17–19% EBITDA margin bracket, targeting 18–20%, and this range is expected to hold even into FY27.
- No price cuts for volume: Management was emphatic that it will not reduce margins to increase volume, stating that once pricing drops, it is difficult to regain, even as the tariff environment creates pressure to compete.
- The tariff margin math is being absorbed, not passed through: While management insists margins remain intact, it acknowledged that "somewhere you need to eat something," implying the company is absorbing part of the tariff impact rather than passing it all to customers or cutting costs fully.
Parag Jhaveri: "That is not the step we are willing to take because once you drop the pricing, difficult to regain."
R&D and Capacity: Building the Pipeline While Capex Waits for Clarity
- New R&D laboratory commissioned: A ₹23 crores R&D facility went live on 29th October 2025, 15 days before the earnings call, with team size increased and several senior scientists joining in the last six months.
- Product development threshold is high: Management will only initiate new product development when the minimum sales value is ₹50–100 crores, ensuring R&D spend is directed at commercially material opportunities.
- Capex is on a short leash: Of the ₹100 crores planned for this year, ₹23 crores went to R&D, ₹20 crores to additional assets for capacity increase, and ₹45 crores remains unspent while management waits for clarity on tariffs and the business climate; no new additional capex will be committed until that clarity arrives, with only maintenance capex assumed for FY27.
- Capacity expansion timeline: New production lines are expected to come on stream in January or February 2026, and the remaining ₹50 crores of capex may take 18–24 months instead of the originally planned 12 months.
- Lube packaging tailwind: Lube packaging players setting up plants in India due to domestic procurement focus is beneficial to Yasho as they need raw material; it is a slow process but is giving a boost.
Parag Jhaveri: "For us to have any new product develop at minimum-to-minimum sales value, we look at INR50 crores to INR100 crores, then only we start getting into that chemistry and then we develop it."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue | ₹800–₹850 crores (revised from ₹900–₹1,000 crores) | FY26 |
| Inventory reduction | Bring inventory from 210 days to 160–175 days | By March 2026 |
| US revenue recovery | Regain US business to prior 25% of revenue share | Current quarter and next quarter |
| EBITDA margin | Maintain 17–19% range, targeting 18–20% | FY26 and FY27 |
| Gross margin | Remain within 38–42%, working toward 40% plus | Ongoing |
| Debt-to-EBITDA | Close to 3.5 or between 3 to 3.5 | By FY27 |
| New capacity on stream | Part of new capacity to begin production | January or February 2026 |
| Export share | Exports to reach almost 70% of total revenue | Within 6 to 18 months |
| New capex commitment | No additional capex beyond maintenance until tariff clarity | FY27 |
| Remaining ₹50 crores capex | Completion in 18–24 months (vs original 12 months) | 18–24 months from now |
| Asset turnover | 3x target | 3 to 4 years down the line |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹183.6 cr, +9.6% YoY |
| H1 FY26 revenue | ₹382.6 cr, +11.8% YoY |
| H1 FY26 volume growth | 30% YoY |
| EBITDA margin | 18.2% |
| PAT margin | 2.65% |
| Gross margin | 42%, average range 38% to 42% |
| Full-year revenue guidance | ₹800 cr to ₹850 cr, revised from ₹900 cr to ₹1,000 cr |
| FY27 EBITDA margin guidance | 17% to 19% |
| Revenue at optimal capacity (both units) | ~₹1,200 cr |
| Pakhajan facility utilization | below 50%, dipped from prior ~50% |
| US revenue share | 25% of total business; of that, at least 40% affected by tariff |
| Inventory days | 210 days, target 160 to 175 days by March |
| Receivables days | 60 days, sustainable range 60 to 70 days |
| Debt-to-EBITDA target by FY27 | 3 to 3.5x |
| Industrial segment revenue share | 85% to 86% |
| R&D opex (FY26) | ~₹5 cr, up from ~₹1 cr in prior year |
| Long-term supply agreement annual revenue (from FY27) | ~₹150 cr |